Clinical significance of miR‑372 and miR‑495 in acute myeloid leukemia

Zhang,Wei; Wan,Bo; Liu,Bei; Wu,Shiwen; Zhao,Li

doi:10.3892/ol.2020.11748

Clinical significance of miR‑372 and miR‑495 in acute myeloid leukemia

Authors:
- Wei Zhang
- Bo Wan
- Bei Liu
- Shiwen Wu
- Li Zhao
View Affiliations

Affiliations: Central Laboratory, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Rehabilitation Medicine, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China, Department of Hematology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Laboratory Medicine, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
Published online on: June 17, 2020 https://doi.org/10.3892/ol.2020.11748
Pages: 1938-1944
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the clinical significance of miR‑372 and miR‑495 in acute myeloid leukemia (AML). Eighty‑one AML patients (research group) admitted to the First Hospital of Lanzhou University from March 2012 to January 2014 were selected, and 60 healthy persons (control group) were selected. The expression levels of miR‑372 and miR‑495 in the peripheral blood of the subjects were detected by reverse transcriptase quantitative PCR, and their diagnostic and prognostic values in AML were analyzed. The miR‑372 expression level in the peripheral blood of patients in the research group was significantly higher than that in the control group (P<0.05), and the miR‑495 level was significantly lower than that in the control group (P<0.05). The area under the curve (AUC), sensitivity, and specificity of miR‑372 combined with miR‑495 in the diagnosis of AML were 0.925, 86.43, and 93.33% respectively. The 5‑year survival rate of patients with high expression of miR‑372 was lower than that of those with low expression of miR‑372 (P<0.05), and the 5‑year survival rate of patients with high expression of miR‑495 was higher than that of those with low expression of miR‑495 (P<0.05). miR‑372 and miR‑495 were independent risk factors for the prognosis and survival of AML patients. miR‑372 expression increased in AML, while miR‑495 decreased. miR‑372 and miR‑495 are effective indicators for the early diagnosis and prognosis of AML.

View Figures

View References

1	Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, et al: A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 8:1566–1581. 2018. View Article : Google Scholar : PubMed/NCBI
2	Parkin B, Londoño-Joshi A, Kang Q, Tewari M, Rhim AD and Malek SN: Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. J Clin Invest. 127:3484–3495. 2017. View Article : Google Scholar : PubMed/NCBI
3	Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, Barda N, Zuzarte PC, Heisler L, Sundaravadanam Y, et al: Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 559:400–404. 2018. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: Metazoan MicroRNAs. Cell. 173:20–51. 2018. View Article : Google Scholar : PubMed/NCBI
5	Berindan-Neagoe I, Monroig PC, Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
6	Trino S, Lamorte D, Caivano A, Laurenzana I, Tagliaferri D, Falco G, Del Vecchio L, Musto P and De Luca L: MicroRNAs as new biomarkers for diagnosis and prognosis, and as potential therapeutic targets in acute myeloid leukemia. Int J Mol Sci. 19(pii): E4602018. View Article : Google Scholar : PubMed/NCBI
7	Wallace JA and O'Connell RM: MicroRNAs and acute myeloid leukemia: Therapeutic implications and emerging concepts. Blood. 130:1290–1301. 2017. View Article : Google Scholar : PubMed/NCBI
8	Zhao Q, Feng J, Li W, Shen K, Chen S, Xie Y, Zhao C and Hou Y: Expression and mechanism of plasma miR-372 in acute myeloid leukemia patients. J Pract Med. 34:2030–2034. 2018.
9	Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, et al: miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 109:19397–19402. 2012. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z, Xia LY, Chen LR, Wang Y, Wang XZ, Bi LX, et al: miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep. 39:2713–2722. 2012. View Article : Google Scholar : PubMed/NCBI
12	Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M and Ohyashiki K: Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: In vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes. 3:3472010. View Article : Google Scholar : PubMed/NCBI
13	Yan J, Wu G, Chen J, Xiong L, Chen G and Li P: Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia. Cancer Biomark. 22:73–78. 2018. View Article : Google Scholar : PubMed/NCBI
14	Huang X, Huang M, Kong L and Li Y: miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma. Cell Prolif. 48:593–599. 2015. View Article : Google Scholar : PubMed/NCBI
15	Yeh LY, Liu CJ, Wong YK, Chang C, Lin SC and Chang KW: miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo. Oncotarget. 6:6062–6075. 2015. View Article : Google Scholar : PubMed/NCBI
16	Mao Y, Li L, Liu J, Wang L and Zhou Y: miR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1. Oncotarget. 7:51223–51236. 2016. View Article : Google Scholar : PubMed/NCBI
17	Chen Y, Luo D, Tian W, Li Z and Zhang X: Demethylation of miR-495 inhibits cell proliferation, migration and promotes apoptosis by targeting STAT-3 in breast cancer. Oncol Rep. 37:3581–3589. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yu J, Jin L, Jiang L, Gao L, Zhou J, Hu Y, Li W, Zhi Q and Zhu X: Serum miR-372 is a diagnostic and prognostic biomarker in patients with early colorectal cancer. Anticancer Agents Med Chem. 16:424–431. 2016. View Article : Google Scholar : PubMed/NCBI
19	Wang C, Yun Z, Zhao T, Liu X and Ma X: miR-495 is a predictive biomarker that downregulates GFI1 expression in medulloblastoma. Cell Physiol Biochem. 36:1430–1439. 2015. View Article : Google Scholar : PubMed/NCBI
20	Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, et al: TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 118:3803–3810. 2011. View Article : Google Scholar : PubMed/NCBI
21	Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR and Boeckh M: CMV reactivation after allogeneic HCT and relapse risk: Evidence for early protection in acute myeloid leukemia. Blood. 122:1316–1324. 2013. View Article : Google Scholar : PubMed/NCBI
22	Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, et al: Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 29:2410–2415. 2011. View Article : Google Scholar : PubMed/NCBI
23	Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, et al: Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 29:2889–2896. 2011. View Article : Google Scholar : PubMed/NCBI
24	Gu H, Guo X, Zou L, Zhu H and Zhang J: Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem. 375:23–30. 2013.PubMed/NCBI
25	Michallet M, Bénet T, Sobh M, Kraghel S, El Hamri M, Cannas G, Nicolini FE, Labussière H, Ducastelle S, Barraco F, et al: Invasive aspergillosis: An important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis. 31:991–997. 2012. View Article : Google Scholar : PubMed/NCBI
26	Deschler B and Lübbert M: Acute myeloid leukemia: Epidemiology and etiology. Cancer. 107:2099–2107. 2006. View Article : Google Scholar : PubMed/NCBI